Lobe Sciences Ltd.
LOBEF · OTC
8/31/2024 | 8/31/2023 | 8/31/2022 | 8/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,603 | $2,382 | $800 | $660 |
| - Cash | $238 | $140 | $908 | $1,142 |
| + Debt | $1,747 | $333 | $0 | $0 |
| Enterprise Value | $4,112 | $2,574 | -$107 | -$482 |
| Revenue | $136 | $841 | $0 | $0 |
| % Growth | -83.8% | – | – | – |
| Gross Profit | $134 | $817 | -$10 | $0 |
| % Margin | 98.7% | 97.1% | – | – |
| EBITDA | -$4,116 | -$4,420 | -$4,113 | -$6,159 |
| % Margin | -3,021.9% | -525.9% | – | – |
| Net Income | -$4,421 | -$4,707 | -$12,253 | -$9,658 |
| % Margin | -3,245.8% | -560% | – | – |
| EPS Diluted | -0.036 | -0.045 | -0.32 | -0.3 |
| % Growth | 19.7% | 85.9% | -6.7% | – |
| Operating Cash Flow | -$462 | -$1,719 | -$2,731 | -$5,037 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$462 | -$1,719 | -$2,731 | -$5,037 |